Hematologic Oncology

Lori Muffly, MD, discusses the clinical outcomes with the use of a novel conditioning regimen featuring the anti-CD117 monoclonal antibody briquilimab plus low-dose irradiation and fludarabine prior to allogeneic hemopoietic stem cell transplant in older patients with acute myeloid leukemia.

Warren Fingrut, MD, discusses the association between non-European ancestry and low socioeconomic status with the receipt of HLA-disparate grafts.

Joanne Kurtzberg, MD, discusses the long-term survival outcomes from an observational cohort study evaluating remestemcel-L in pediatric patients with steroid-refractory acute graft-vs-host disease.

With acquired resistance patterns emerging for nearly every agent, hematologic experts are looking closely at sequencing patterns, but more work needs to be done in aggressive malignancies in which mutations associated with resistance may be present before therapy even begins.

A comprehensive review of novel venetoclax-based combination therapy in patients unfit for intensive chemotherapy who are diagnosed with AML.

In the setting of IDH-mutated AML, panelists consider optimal treatment options in patients unfit for intensive chemotherapy.

Closing out his discussion on tumor lysis syndrome, Anthony Perissinotti, PharmD, BCOP, shares practical advice on its identification and management.

Kathryn Maples, PharmD, BCOP, discusses recent approvals, updated labeling, and drug removals across leukemia, lymphoma, and multiple myeloma.

Amer M. Beitinjaneh, MD, discusses updated results from phase 3 ALLELE trial investigating the use of tabelecleucel in Epstein-Barr Virus–positive post-transplant lymphoproliferative disease following allogeneic hematopoietic stem cell transplant or solid organ transplant after failure of rituximab with or without chemotherapy.

For patients with acute myeloid leukemia, advances in targeting minimal residual disease represents the next wave of advances in the field and is necessary to cure this disease.

Craig Sauter, MD, discusses prominent questions surrounding new and emerging therapies in the treatment of patients with hematologic malignancies.

Eunice Wang, MD, discusses reasons why some older patients with acute myeloid leukemia may not be eligible to receive hypomethylating therapy and highlights ongoing investigations within this older patient population

Andrew Ip, MD, delivers a keynote on the role for liquid biopsy and NGS in hematologic malignancies, including the barriers to implementing seamlessly into clinical practice.

Amandeep Salhotra, MD, discusses efficacy data from a phase 1 trial of Orca-Q in acute and chronic graft-vs-host disease.

Jorge E. Cortes, MD, discusses important questions in acute lymphoblastic leukemia to address, such as improved understanding of the role of allogenic stem cell transplant and the use of tyrosine kinase inhibitor combinations.

Expert hematologic oncologists discuss updates from the ASH 2022 Annual Meeting on emerging therapies for lower-risk MDS.

Following the ASH 2022 Annual Meeting, experts in hematologic oncology review updated data for luspatercept in lower-risk MDS.

Hematologic oncology experts give an overview of first- and second-line treatment options for lower-risk myelodysplastic syndromes.

Experts summarize recent updates on other approved or emerging second-line therapies for lower-risk MDS.

Dr Komrokji presents key data updates from the MEDALIST trial on luspatercept in patients with lower-risk MDS that were presented at the 2022 European Hematology Association (EHA) Congress and the 2022 ASH Annual Meeting.

Guideline-directed treatment strategies available to patients with identified tumor lysis syndrome.

A brief overview of mainstay treatment options in the first-line setting of AML for patients deemed unfit for intensive chemotherapy.

An overview of the prophylactic strategies that may be utilized to reduce the likelihood of tumor lysis syndrome.

Expert oncologists highlight challenges in the setting of TP53-mutated AML and consider appropriate treatment strategies.

The addition of vedolizumab added to standard prophylaxis following unrelated allogeneic hematopoietic stem cell transplantation was superior to placebo at preventing lower gastrointestinal acute graft-vs-host disease.